TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Equity Ab Frankenius Buys 62,972 Shares

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) major shareholder Equity Ab Frankenius purchased 62,972 shares of TriSalus Life Sciences stock in a transaction on Tuesday, December 17th. The stock was bought at an average cost of $3.97 per share, for a total transaction of $249,998.84. Following the transaction, the insider now directly owns 6,230,748 shares in the company, valued at $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

TriSalus Life Sciences Stock Up 12.5 %

NASDAQ:TLSI opened at $4.05 on Friday. The stock has a fifty day simple moving average of $4.14 and a 200 day simple moving average of $4.94. The firm has a market capitalization of $123.48 million, a price-to-earnings ratio of -1.63 and a beta of 0.56. TriSalus Life Sciences, Inc. has a 1-year low of $3.50 and a 1-year high of $10.42.

Analyst Upgrades and Downgrades

Several research firms have commented on TLSI. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Northland Securities started coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target for the company. Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences in a research note on Tuesday. They issued an “overweight” rating and a $10.00 price objective on the stock. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Finally, Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $11.79.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Highbridge Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the second quarter valued at approximately $1,184,000. Wolverine Asset Management LLC acquired a new stake in TriSalus Life Sciences during the 2nd quarter valued at $240,000. Duquesne Family Office LLC lifted its holdings in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares in the last quarter. MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences in the third quarter worth $184,000. Finally, Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences during the third quarter valued at $66,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.